NCT03730961View on ClinicalTrials.gov

An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

December 11, 2019

Study Completion Date

January 9, 2020

Conditions
Cardiac FailureMyocardial FailureCongestive Heart FailureHeart Decompensation
Interventions
DRUG

BMS-986231

Intravenous administration

DRUG

Furosemide

Intravenous administration

DRUG

Placebo

Intravenous administration

Trial Locations (2)

G51 4TF

Glasgow Clinical Research Facility, Glasgow

SW17 0RE

Richmond Pharmacology, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03730961 - An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic | Biotech Hunter | Biotech Hunter